BetterLife Pharma Corp. (OTCMKTS:PVOTF) is a clinical‐stage life sciences company engaged in the development of novel psychedelic and cannabinoid‐inspired therapeutics. The firm’s primary focus lies in advancing microdosing formulations of lysergic acid diethylamide (LSD) and related molecules, leveraging proprietary encapsulation and delivery technologies to improve stability, bioavailability and patient adherence. Through in‐house process development and external collaborations, BetterLife seeks to translate decades of academic research into standardized pharmaceutical products.
The company’s research and development efforts center on its PDM‐007 microdosing program, which employs a patented microencapsulation platform designed to provide controlled release of LSD at sub‐psychedelic dose levels. BetterLife also maintains a growing intellectual property portfolio covering novel synthetic pathways, formulation techniques and analytical methods. In addition to its LSD pipeline, the firm is exploring custom cannabinoid hybrids and other endocannabinoid modulators, all aimed at addressing a range of central nervous system disorders.
BetterLife operates primarily out of its research facilities in Toronto, Canada, and maintains strategic partnerships with leading academic institutions in North America and Europe. Through these collaborations, the company has accessed specialized expertise in pharmacokinetics, neurobiology and clinical trial design, positioning it for early‐phase human studies. While its initial clinical activities are focused on Canadian regulatory pathways, BetterLife is actively preparing for broader market entry in the United States and select European jurisdictions where psychedelic medicine frameworks are evolving.
Founded in 2018, BetterLife Pharma is led by CEO Michael Tan, who brings more than 15 years of experience in pharmaceutical development and venture capital. The senior management team includes Dr. Rebecca Ortiz, Head of Clinical Development, and CFO Daniel Park, a seasoned financial executive in the life sciences sector. Under its current board of directors, which features experts in biotech commercialization and regulatory affairs, the company aims to advance its lead candidates through proof‐of‐concept trials and secure strategic partnerships to support late‐stage development and eventual commercialization.
AI Generated. May Contain Errors.
